APO Research
Talk to an analyst

APO RESEARCH · REPORT

Pharmacogenomics Technology (Theranostics & CDx)

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global Pharmacogenomics Technology (Theranostics & CDx) Industry Growth and Trends Forecast to 2032

29 December 2025103 pages

Choose your research edition.

Industry ResearchPharmacogenomics Technology (Theranostics & CDx) Industry Research Report 2026119 pages · $2,950 USDIndustry Growth & TrendsGlobal Pharmacogenomics Technology (Theranostics & CDx) Industry Growth and Trends Forecast to 2032103 pages · $3,450 USDMarket StructureGlobal Pharmacogenomics Technology (Theranostics & CDx) Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032192 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Pharmacogenomics Technology (Theranostics & CDx) Market Outlook and Growth Opportunities 2026193 pages · $4,250 USDMarket Analysis & ForecastGlobal Pharmacogenomics Technology (Theranostics & CDx) Market Analysis and Forecast 2026-2032192 pages · $4,950 USD

Market perspective

According to APO Research, the global Pharmacogenomics Technology (Theranostics & CDx) market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

Report Scope

This report provides a structured, data-driven view of the global Pharmacogenomics Technology (Theranostics & CDx) market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

Read the full market overview

The Pharmacogenomics Technology (Theranostics & CDx) market size, estimates, and forecasts are presented in terms of revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Pharmacogenomics Technology (Theranostics & CDx) market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Pharmacogenomics Technology (Theranostics & CDx).

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading companies in the global Pharmacogenomics Technology (Theranostics & CDx) market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue and gross margin data by manufacturer for 2021-2026, enabling benchmarking of scale, profitability, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Pharmacogenomics Technology (Theranostics & CDx) Market by Company

Illumina

F. Hoffmann-La Roche

Agilent

Abbott

Thermo Fisher Scientific

Qiagen

Guardant Health

MGI Tech

Amoy Diagnostics

BGI Group

Pharmacogenomics Technology (Theranostics & CDx) Segment by Type

Instruments

Reagents and Consumables

Other

Pharmacogenomics Technology (Theranostics & CDx) Segment by Application

Tumour

Diabetes

Mental Illness

Cardiovascular Disease

Other

Pharmacogenomics Technology (Theranostics & CDx) Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Pharmacogenomics Technology (Theranostics & CDx) market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Pharmacogenomics Technology (Theranostics & CDx) and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Pharmacogenomics Technology (Theranostics & CDx).

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2021-2025, 2026-2031). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 3: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 4: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 5: Detailed analysis of Pharmacogenomics Technology (Theranostics & CDx) companies' competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, revenue by country.

Chapter 12: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Global Pharmacogenomics Technology (Theranostics & CDx) Market Size (US$ Million) Comparison by Region: 2021 VS 2025 VS 2032 Table 2. Global Pharmacogenomics Technology (Theranostics & CDx) Market Size by Region (2021-2026) & (US$ Million) Table 3. Global Pharmacogenomics Technology (Theranostics & CDx) Market Share by Region (2021-2026) Table 4. Global Pharmacogenomics Technology (Theranostics & CDx) Market Size by Region (2027-2032) & (US$ Million) Table 5. Global Pharmacogenomics Technology (Theranostics & CDx) Market Share by Region (2027-2032) Table 6. Global Pharmacogenomics Technology (Theranostics & CDx) Market Size by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 7. Global Pharmacogenomics Technology (Theranostics & CDx) Market Size by Type (2021-2026) & (US$ Million) Table 8. Global Pharmacogenomics Technology (Theranostics & CDx) Market Size Share by Type (2021-2026) Table 9. Global Pharmacogenomics Technology (Theranostics & CDx) Market Size Forecasted by Type (2027-2032) & (US$ Million) Table 10. Global Pharmacogenomics Technology (Theranostics & CDx) Market Size Share Forecasted by Type (2027-2032) Table 11. North America Pharmacogenomics Technology (Theranostics & CDx) Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 12. North America Pharmacogenomics Technology (Theranostics & CDx) Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 13. Europe Pharmacogenomics Technology (Theranostics & CDx) Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 14. Europe Pharmacogenomics Technology (Theranostics & CDx) Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 15. Asia-Pacific Pharmacogenomics Technology (Theranostics & CDx) Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 16. Asia-Pacific Pharmacogenomics Technology (Theranostics & CDx) Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 17. Latin America Pharmacogenomics Technology (Theranostics & CDx) Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 18. Latin America Pharmacogenomics Technology (Theranostics & CDx) Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 19. Middle East and Africa Pharmacogenomics Technology (Theranostics & CDx) Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 20. Middle East and Africa Pharmacogenomics Technology (Theranostics & CDx) Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 21. Global Pharmacogenomics Technology (Theranostics & CDx) Market Size by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 22. Global Pharmacogenomics Technology (Theranostics & CDx) Market Size by Application (2021-2026) & (US$ Million) Table 23. Global Pharmacogenomics Technology (Theranostics & CDx) Market Size Share by Application (2021-2026) Table 24. Global Pharmacogenomics Technology (Theranostics & CDx) Market Size Forecasted by Application (2027-2032) & (US$ Million) Table 25. Global Pharmacogenomics Technology (Theranostics & CDx) Market Size Share Forecasted by Application (2027-2032) Table 26. North America Pharmacogenomics Technology (Theranostics & CDx) Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 27. North America Pharmacogenomics Technology (Theranostics & CDx) Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 28. Europe Pharmacogenomics Technology (Theranostics & CDx) Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 29. Europe Pharmacogenomics Technology (Theranostics & CDx) Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 30. Asia-Pacific Pharmacogenomics Technology (Theranostics & CDx) Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 31. Asia-Pacific Pharmacogenomics Technology (Theranostics & CDx) Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 32. Latin America Pharmacogenomics Technology (Theranostics & CDx) Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 33. Latin America Pharmacogenomics Technology (Theranostics & CDx) Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 34. Middle East and Africa Pharmacogenomics Technology (Theranostics & CDx) Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 35. Middle East and Africa Pharmacogenomics Technology (Theranostics & CDx) Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 36. Pharmacogenomics Technology (Theranostics & CDx) Industry Trends Table 37. Pharmacogenomics Technology (Theranostics & CDx) Industry Drivers Table 38. Pharmacogenomics Technology (Theranostics & CDx) Industry Opportunities and Challenges Table 39. Pharmacogenomics Technology (Theranostics & CDx) Industry Restraints Table 40. Global Pharmacogenomics Technology (Theranostics & CDx) Revenue by Company (US$ Million) & (2021-2026) Table 41. Global Pharmacogenomics Technology (Theranostics & CDx) Revenue Market Share by Company (2021-2026) Table 42. Global Pharmacogenomics Technology (Theranostics & CDx) Industry Company Ranking, 2024 VS 2025 VS 2026 Table 43. Global Pharmacogenomics Technology (Theranostics & CDx) Key Company Headquarters & Area Served Table 44. Global Pharmacogenomics Technology (Theranostics & CDx) Company, Product Type & Application Table 45. Global Pharmacogenomics Technology (Theranostics & CDx) Company Commercialization Time Table 46. Global Company Market Concentration Ratio (CR5 and HHI) Table 47. Global Pharmacogenomics Technology (Theranostics & CDx) by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 48. Illumina Company Information Table 49. Illumina Business Overview Table 50. Illumina Pharmacogenomics Technology (Theranostics & CDx) Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 51. Illumina Pharmacogenomics Technology (Theranostics & CDx) Product Portfolio Table 52. Illumina Recent Development Table 53. F. Hoffmann-La Roche Company Information Table 54. F. Hoffmann-La Roche Business Overview Table 55. F. Hoffmann-La Roche Pharmacogenomics Technology (Theranostics & CDx) Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 56. F. Hoffmann-La Roche Pharmacogenomics Technology (Theranostics & CDx) Product Portfolio Table 57. F. Hoffmann-La Roche Recent Development Table 58. Agilent Company Information Table 59. Agilent Business Overview Table 60. Agilent Pharmacogenomics Technology (Theranostics & CDx) Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 61. Agilent Pharmacogenomics Technology (Theranostics & CDx) Product Portfolio Table 62. Agilent Recent Development Table 63. Abbott Company Information Table 64. Abbott Business Overview Table 65. Abbott Pharmacogenomics Technology (Theranostics & CDx) Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 66. Abbott Pharmacogenomics Technology (Theranostics & CDx) Product Portfolio Table 67. Abbott Recent Development Table 68. Thermo Fisher Scientific Company Information Table 69. Thermo Fisher Scientific Business Overview Table 70. Thermo Fisher Scientific Pharmacogenomics Technology (Theranostics & CDx) Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 71. Thermo Fisher Scientific Pharmacogenomics Technology (Theranostics & CDx) Product Portfolio Table 72. Thermo Fisher Scientific Recent Development Table 73. Qiagen Company Information Table 74. Qiagen Business Overview Table 75. Qiagen Pharmacogenomics Technology (Theranostics & CDx) Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 76. Qiagen Pharmacogenomics Technology (Theranostics & CDx) Product Portfolio Table 77. Qiagen Recent Development Table 78. Guardant Health Company Information Table 79. Guardant Health Business Overview Table 80. Guardant Health Pharmacogenomics Technology (Theranostics & CDx) Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 81. Guardant Health Pharmacogenomics Technology (Theranostics & CDx) Product Portfolio Table 82. Guardant Health Recent Development Table 83. MGI Tech Company Information Table 84. MGI Tech Business Overview Table 85. MGI Tech Pharmacogenomics Technology (Theranostics & CDx) Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 86. MGI Tech Pharmacogenomics Technology (Theranostics & CDx) Product Portfolio Table 87. MGI Tech Recent Development Table 88. Amoy Diagnostics Company Information Table 89. Amoy Diagnostics Business Overview Table 90. Amoy Diagnostics Pharmacogenomics Technology (Theranostics & CDx) Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 91. Amoy Diagnostics Pharmacogenomics Technology (Theranostics & CDx) Product Portfolio Table 92. Amoy Diagnostics Recent Development Table 93. BGI Group Company Information Table 94. BGI Group Business Overview Table 95. BGI Group Pharmacogenomics Technology (Theranostics & CDx) Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 96. BGI Group Pharmacogenomics Technology (Theranostics & CDx) Product Portfolio Table 97. BGI Group Recent Development Table 98. North America Pharmacogenomics Technology (Theranostics & CDx) Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 99. North America Pharmacogenomics Technology (Theranostics & CDx) Market Size by Country (2021-2026) & (US$ Million) Table 100. North America Pharmacogenomics Technology (Theranostics & CDx) Market Share by Country (2021-2026) Table 101. North America Pharmacogenomics Technology (Theranostics & CDx) Market Size Forecast by Country (2027-2032) & (US$ Million) Table 102. North America Pharmacogenomics Technology (Theranostics & CDx) Market Share Forecast by Country (2027-2032) Table 103. Europe Pharmacogenomics Technology (Theranostics & CDx) Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 104. Europe Pharmacogenomics Technology (Theranostics & CDx) Market Size by Country (2021-2026) & (US$ Million) Table 105. Europe Pharmacogenomics Technology (Theranostics & CDx) Market Share by Country (2021-2026) Table 106. Europe Pharmacogenomics Technology (Theranostics & CDx) Market Size Forecast by Country (2027-2032) & (US$ Million) Table 107. Europe Pharmacogenomics Technology (Theranostics & CDx) Market Share Forecast by Country (2027-2032) Table 108. Asia-Pacific Pharmacogenomics Technology (Theranostics & CDx) Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 109. Asia-Pacific Pharmacogenomics Technology (Theranostics & CDx) Market Size by Country (2021-2026) & (US$ Million) Table 110. Asia-Pacific Pharmacogenomics Technology (Theranostics & CDx) Market Share by Country (2021-2026) Table 111. Asia-Pacific Pharmacogenomics Technology (Theranostics & CDx) Market Size Forecast by Country (2027-2032) & (US$ Million) Table 112. Asia-Pacific Pharmacogenomics Technology (Theranostics & CDx) Market Share Forecast by Country (2027-2032) Table 113. Latin America Pharmacogenomics Technology (Theranostics & CDx) Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 114. Latin America Pharmacogenomics Technology (Theranostics & CDx) Market Size by Country (2021-2026) & (US$ Million) Table 115. Latin America Pharmacogenomics Technology (Theranostics & CDx) Market Share by Country (2021-2026) Table 116. Latin America Pharmacogenomics Technology (Theranostics & CDx) Market Size Forecast by Country (2027-2032) & (US$ Million) Table 117. Latin America Pharmacogenomics Technology (Theranostics & CDx) Market Share Forecast by Country (2027-2032) Table 118. Middle East & Africa Pharmacogenomics Technology (Theranostics & CDx) Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 119. Middle East & Africa Pharmacogenomics Technology (Theranostics & CDx) Market Size by Country (2021-2026) & (US$ Million) Table 120. Middle East & Africa Pharmacogenomics Technology (Theranostics & CDx) Market Share by Country (2021-2026) Table 121. Middle East & Africa Pharmacogenomics Technology (Theranostics & CDx) Market Size Forecast by Country (2027-2032) & (US$ Million) Table 122. Middle East & Africa Pharmacogenomics Technology (Theranostics & CDx) Market Share Forecast by Country (2027-2032) Table 123. Research Programs/Design for This Report Table 124. Authors List of This Report Table 125. Secondary Sources List of Figures Figure 1.List of Figures Figure 2. Pharmacogenomics Technology (Theranostics & CDx) Product Image Figure 3. Global Pharmacogenomics Technology (Theranostics & CDx) Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 4. Global Pharmacogenomics Technology (Theranostics & CDx) Market Size (2021-2032) & (US$ Million) Figure 5. Global Pharmacogenomics Technology (Theranostics & CDx) Market Share by Region: 2025 VS 2032 Figure 6. Global Pharmacogenomics Technology (Theranostics & CDx) Market Share by Region (2021-2032) Figure 7. North America Pharmacogenomics Technology (Theranostics & CDx) Market Size Growth Rate (2021-2032) & (US$ Million) Figure 8. Europe Pharmacogenomics Technology (Theranostics & CDx) Market Size Growth Rate (2021-2032) & (US$ Million) Figure 9. Asia-Pacific Pharmacogenomics Technology (Theranostics & CDx) Market Size Growth Rate (2021-2032) & (US$ Million) Figure 10. Latin America Pharmacogenomics Technology (Theranostics & CDx) Market Size Growth Rate (2021-2032) & (US$ Million) Figure 11. Middle East & Africa Pharmacogenomics Technology (Theranostics & CDx) Market Size Growth Rate (2021-2032) & (US$ Million) Figure 12. Instruments Image Figure 13. Global Instruments Market Size YoY Growth (2021-2032) & (US$ Million) Figure 14. Reagents and Consumables Image Figure 15. Global Reagents and Consumables Market Size YoY Growth (2021-2032) & (US$ Million) Figure 16. Other Image Figure 17. Global Other Market Size YoY Growth (2021-2032) & (US$ Million) Figure 18. Global Pharmacogenomics Technology (Theranostics & CDx) Market Size Overview by Type (2021-2032) & (US$ Million) Figure 19. Global Pharmacogenomics Technology (Theranostics & CDx) Market Share by Type 2025 VS 2032 Figure 20. North America Pharmacogenomics Technology (Theranostics & CDx) Market Size Share by Type (2021-2032) Figure 21. Europe Pharmacogenomics Technology (Theranostics & CDx) Market Size Share by Type (2021-2032) Figure 22. Asia-Pacific Pharmacogenomics Technology (Theranostics & CDx) Market Size Share by Type (2021-2032) Figure 23. Latin America Pharmacogenomics Technology (Theranostics & CDx) Market Size Share by Type (2021-2032) Figure 24. Middle East and Africa Pharmacogenomics Technology (Theranostics & CDx) Market Size Share by Type (2021-2032) Figure 25. Tumour Image Figure 26. Global Tumour Market Size YoY Growth (2021-2032) & (US$ Million) Figure 27. Diabetes Image Figure 28. Global Diabetes Market Size YoY Growth (2021-2032) & (US$ Million) Figure 29. Mental Illness Image Figure 30. Global Mental Illness Market Size YoY Growth (2021-2032) & (US$ Million) Figure 31. Cardiovascular Disease Image Figure 32. Global Cardiovascular Disease Market Size YoY Growth (2021-2032) & (US$ Million) Figure 33. Other Image Figure 34. Global Other Market Size YoY Growth (2021-2032) & (US$ Million) Figure 35. Global Pharmacogenomics Technology (Theranostics & CDx) Market Size Overview by Application (2021-2032) & (US$ Million) Figure 36. Global Pharmacogenomics Technology (Theranostics & CDx) Market Share by Application 2025 VS 2032 Figure 37. North America Pharmacogenomics Technology (Theranostics & CDx) Market Size Share by Application (2021-2032) Figure 38. Europe Pharmacogenomics Technology (Theranostics & CDx) Market Size Share by Application (2021-2032) Figure 39. Asia-Pacific Pharmacogenomics Technology (Theranostics & CDx) Market Size Share by Application (2021-2032) Figure 40. Latin America Pharmacogenomics Technology (Theranostics & CDx) Market Size Share by Application (2021-2032) Figure 41. Middle East and Africa Pharmacogenomics Technology (Theranostics & CDx) Market Size Share by Application (2021-2032) Figure 42. Global Top 5 and 10 Pharmacogenomics Technology (Theranostics & CDx) Players Market Share by Revenue in 2025 Figure 43. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 44. North America Pharmacogenomics Technology (Theranostics & CDx) Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 45. North America Pharmacogenomics Technology (Theranostics & CDx) Market Share by Country: 2021 VS 2025 VS 2032 Figure 46. North America Pharmacogenomics Technology (Theranostics & CDx) Market Share by Country (2021-2032) Figure 47. Europe Pharmacogenomics Technology (Theranostics & CDx) Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 48. Europe Pharmacogenomics Technology (Theranostics & CDx) Market Share by Country: 2021 VS 2025 VS 2032 Figure 49. Europe Pharmacogenomics Technology (Theranostics & CDx) Market Share by Country (2021-2032) Figure 50. Asia-Pacific Pharmacogenomics Technology (Theranostics & CDx) Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 51. Asia-Pacific Pharmacogenomics Technology (Theranostics & CDx) Market Share by Country: 2021 VS 2025 VS 2032 Figure 52. Asia-Pacific Pharmacogenomics Technology (Theranostics & CDx) Market Share by Country (2021-2032) Figure 53. Latin America Pharmacogenomics Technology (Theranostics & CDx) Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 54. Latin America Pharmacogenomics Technology (Theranostics & CDx) Market Share by Country: 2021 VS 2025 VS 2032 Figure 55. Latin America Pharmacogenomics Technology (Theranostics & CDx) Market Share by Country (2021-2032) Figure 56. Middle East & Africa Pharmacogenomics Technology (Theranostics & CDx) Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 57. Middle East & Africa Pharmacogenomics Technology (Theranostics & CDx) Market Share by Country: 2021 VS 2025 VS 2032 Figure 58. Middle East & Africa Pharmacogenomics Technology (Theranostics & CDx) Market Share by Country (2021-2032) Figure 59. Years Considered Figure 60. Research Process Figure 61. Key Executives Interviewed

Scope & coverage.

Types
  • Instruments
  • Reagents and Consumables
  • Other
Applications
  • Tumour
  • Diabetes
  • Mental Illness
  • Cardiovascular Disease
  • Other
Companies covered
  • Illumina
  • F. Hoffmann-La Roche
  • Agilent
  • Abbott
  • Thermo Fisher Scientific
  • Qiagen
  • Guardant Health
  • MGI Tech
  • Amoy Diagnostics
  • BGI Group

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.3 Global Pharmacogenomics Technology (Theranostics & CDx) Market Size Overview by Region 2021 VS 2025 VS 2032
  4. 1.4 Global Pharmacogenomics Technology (Theranostics & CDx) Market Size by Region (2021-2032)
  5. 1.4.1 Global Pharmacogenomics Technology (Theranostics & CDx) Market Size by Region (2021-2026)
  6. 1.4.2 Global Pharmacogenomics Technology (Theranostics & CDx) Market Size by Region (2027-2032)
  7. 1.5 Key Regions Pharmacogenomics Technology (Theranostics & CDx) Market Size (2021-2032)
  8. 1.5.1 North America Pharmacogenomics Technology (Theranostics & CDx) Market Size Growth Rate (2021-2032)
  9. 1.5.2 Europe Pharmacogenomics Technology (Theranostics & CDx) Market Size Growth Rate (2021-2032)
  10. 1.5.3 Asia-Pacific Pharmacogenomics Technology (Theranostics & CDx) Market Size Growth Rate (2021-2032)
  11. 1.5.4 South America Pharmacogenomics Technology (Theranostics & CDx) Market Size Growth Rate (2021-2032)
  12. 1.5.5 Middle East & Africa Pharmacogenomics Technology (Theranostics & CDx) Market Size Growth Rate (2021-2032)
2 Pharmacogenomics Technology (Theranostics & CDx) Market by Type
  1. 2.1 Type Introduction
  2. 2.1.1 Instruments
  3. 2.1.2 Reagents and Consumables
  4. 2.1.3 Other
  5. 2.2 Global Pharmacogenomics Technology (Theranostics & CDx) Market Size by Type
  6. 2.2.1 Global Pharmacogenomics Technology (Theranostics & CDx) Market Size Overview by Type (2021-2032)
  7. 2.2.2 Global Pharmacogenomics Technology (Theranostics & CDx) Historic Market Size Review by Type (2021-2026)
  8. 2.2.3 Global Pharmacogenomics Technology (Theranostics & CDx) Market Size Forecasted by Type (2027-2032)
  9. 2.3 Global Pharmacogenomics Technology (Theranostics & CDx) Market Size by Regions
  10. 2.3.1 North America Pharmacogenomics Technology (Theranostics & CDx) Market Size Breakdown by Type (2021-2026)
  11. 2.3.2 Europe Pharmacogenomics Technology (Theranostics & CDx) Market Size Breakdown by Type (2021-2026)
  12. 2.3.3 Asia-Pacific Pharmacogenomics Technology (Theranostics & CDx) Market Size Breakdown by Type (2021-2026)
  13. 2.3.4 South America Pharmacogenomics Technology (Theranostics & CDx) Market Size Breakdown by Type (2021-2026)
  14. 2.3.5 Middle East and Africa Pharmacogenomics Technology (Theranostics & CDx) Market Size Breakdown by Type (2021-2026)
3 Pharmacogenomics Technology (Theranostics & CDx) Market by Application
  1. 3.1 Type Introduction
  2. 3.1.1 Tumour
  3. 3.1.2 Diabetes
  4. 3.1.3 Mental Illness
  5. 3.1.4 Cardiovascular Disease
  6. 3.1.5 Other
  7. 3.2 Global Pharmacogenomics Technology (Theranostics & CDx) Market Size by Application
  8. 3.2.1 Global Pharmacogenomics Technology (Theranostics & CDx) Market Size Overview by Application (2021-2032)
  9. 3.2.2 Global Pharmacogenomics Technology (Theranostics & CDx) Historic Market Size Review by Application (2021-2026)
  10. 3.2.3 Global Pharmacogenomics Technology (Theranostics & CDx) Market Size Forecasted by Application (2027-2032)
  11. 3.3 Global Pharmacogenomics Technology (Theranostics & CDx) Market Size by Regions
  12. 3.3.1 North America Pharmacogenomics Technology (Theranostics & CDx) Market Size Breakdown by Application (2021-2026)
  13. 3.3.2 Europe Pharmacogenomics Technology (Theranostics & CDx) Market Size Breakdown by Application (2021-2026)
  14. 3.3.3 Asia-Pacific Pharmacogenomics Technology (Theranostics & CDx) Market Size Breakdown by Application (2021-2026)
  15. 3.3.4 South America Pharmacogenomics Technology (Theranostics & CDx) Market Size Breakdown by Application (2021-2026)
  16. 3.3.5 Middle East and Africa Pharmacogenomics Technology (Theranostics & CDx) Market Size Breakdown by Application (2021-2026)
4 Global Market Dynamics
  1. 4.1 Pharmacogenomics Technology (Theranostics & CDx) Industry Trends
  2. 4.2 Pharmacogenomics Technology (Theranostics & CDx) Industry Drivers
  3. 4.3 Pharmacogenomics Technology (Theranostics & CDx) Industry Opportunities and Challenges
  4. 4.4 Pharmacogenomics Technology (Theranostics & CDx) Industry Restraints
5 Competitive Insights by Company
  1. 5.1 Global Top Players by Pharmacogenomics Technology (Theranostics & CDx) Revenue (2021-2026)
  2. 5.2 Global Pharmacogenomics Technology (Theranostics & CDx) Industry Company Ranking, 2024 VS 2025 VS 2026
  3. 5.3 Global Pharmacogenomics Technology (Theranostics & CDx) Key Company Headquarters & Area Served
  4. 5.4 Global Pharmacogenomics Technology (Theranostics & CDx) Company, Product Type & Application
  5. 5.5 Global Pharmacogenomics Technology (Theranostics & CDx) Company Commercialization Time
  6. 5.6 Market Competitive Analysis
  7. 5.6.1 Global Pharmacogenomics Technology (Theranostics & CDx) Market CR5 and HHI
  8. 5.6.2 Global Top 5 and 10 Pharmacogenomics Technology (Theranostics & CDx) Players Market Share by Revenue in 2025
  9. 5.6.3 2025 Pharmacogenomics Technology (Theranostics & CDx) Tier 1, Tier 2, and Tier 3
6 Company Profiles
  1. 6.1 Illumina
  2. 6.1.1 Illumina Company Information
  3. 6.1.2 Illumina Business Overview
  4. 6.1.3 Illumina Pharmacogenomics Technology (Theranostics & CDx) Revenue, Global Share and Gross Margin (2021-2026)
  5. 6.1.4 Illumina Pharmacogenomics Technology (Theranostics & CDx) Product Portfolio
  6. 6.1.5 Illumina Recent Developments
  7. 6.2 F. Hoffmann-La Roche
  8. 6.2.1 F. Hoffmann-La Roche Company Information
  9. 6.2.2 F. Hoffmann-La Roche Business Overview
  10. 6.2.3 F. Hoffmann-La Roche Pharmacogenomics Technology (Theranostics & CDx) Revenue, Global Share and Gross Margin (2021-2026)
  11. 6.2.4 F. Hoffmann-La Roche Pharmacogenomics Technology (Theranostics & CDx) Product Portfolio
  12. 6.2.5 F. Hoffmann-La Roche Recent Developments
  13. 6.3 Agilent
  14. 6.3.1 Agilent Company Information
  15. 6.3.2 Agilent Business Overview
  16. 6.3.3 Agilent Pharmacogenomics Technology (Theranostics & CDx) Revenue, Global Share and Gross Margin (2021-2026)
  17. 6.3.4 Agilent Pharmacogenomics Technology (Theranostics & CDx) Product Portfolio
  18. 6.3.5 Agilent Recent Developments
  19. 6.4 Abbott
  20. 6.4.1 Abbott Company Information
  21. 6.4.2 Abbott Business Overview
  22. 6.4.3 Abbott Pharmacogenomics Technology (Theranostics & CDx) Revenue, Global Share and Gross Margin (2021-2026)
  23. 6.4.4 Abbott Pharmacogenomics Technology (Theranostics & CDx) Product Portfolio
  24. 6.4.5 Abbott Recent Developments
  25. 6.5 Thermo Fisher Scientific
  26. 6.5.1 Thermo Fisher Scientific Company Information
  27. 6.5.2 Thermo Fisher Scientific Business Overview
  28. 6.5.3 Thermo Fisher Scientific Pharmacogenomics Technology (Theranostics & CDx) Revenue, Global Share and Gross Margin (2021-2026)
  29. 6.5.4 Thermo Fisher Scientific Pharmacogenomics Technology (Theranostics & CDx) Product Portfolio
  30. 6.5.5 Thermo Fisher Scientific Recent Developments
  31. 6.6 Qiagen
  32. 6.6.1 Qiagen Company Information
  33. 6.6.2 Qiagen Business Overview
  34. 6.6.3 Qiagen Pharmacogenomics Technology (Theranostics & CDx) Revenue, Global Share and Gross Margin (2021-2026)
  35. 6.6.4 Qiagen Pharmacogenomics Technology (Theranostics & CDx) Product Portfolio
  36. 6.6.5 Qiagen Recent Developments
  37. 6.7 Guardant Health
  38. 6.7.1 Guardant Health Company Information
  39. 6.7.2 Guardant Health Business Overview
  40. 6.7.3 Guardant Health Pharmacogenomics Technology (Theranostics & CDx) Revenue, Global Share and Gross Margin (2021-2026)
  41. 6.7.4 Guardant Health Pharmacogenomics Technology (Theranostics & CDx) Product Portfolio
  42. 6.7.5 Guardant Health Recent Developments
  43. 6.8 MGI Tech
  44. 6.8.1 MGI Tech Company Information
  45. 6.8.2 MGI Tech Business Overview
  46. 6.8.3 MGI Tech Pharmacogenomics Technology (Theranostics & CDx) Revenue, Global Share and Gross Margin (2021-2026)
  47. 6.8.4 MGI Tech Pharmacogenomics Technology (Theranostics & CDx) Product Portfolio
  48. 6.8.5 MGI Tech Recent Developments
  49. 6.9 Amoy Diagnostics
  50. 6.9.1 Amoy Diagnostics Company Information
  51. 6.9.2 Amoy Diagnostics Business Overview
  52. 6.9.3 Amoy Diagnostics Pharmacogenomics Technology (Theranostics & CDx) Revenue, Global Share and Gross Margin (2021-2026)
  53. 6.9.4 Amoy Diagnostics Pharmacogenomics Technology (Theranostics & CDx) Product Portfolio
  54. 6.9.5 Amoy Diagnostics Recent Developments
  55. 6.10 BGI Group
  56. 6.10.1 BGI Group Company Information
  57. 6.10.2 BGI Group Business Overview
  58. 6.10.3 BGI Group Pharmacogenomics Technology (Theranostics & CDx) Revenue, Global Share and Gross Margin (2021-2026)
  59. 6.10.4 BGI Group Pharmacogenomics Technology (Theranostics & CDx) Product Portfolio
  60. 6.10.5 BGI Group Recent Developments
7 North America
  1. 7.1 North America Pharmacogenomics Technology (Theranostics & CDx) Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 7.2 North America Pharmacogenomics Technology (Theranostics & CDx) Market Size by Country (2021-2026)
  3. 7.3 North America Pharmacogenomics Technology (Theranostics & CDx) Market Size Forecast by Country (2027-2032)
8 Europe
  1. 8.1 Europe Pharmacogenomics Technology (Theranostics & CDx) Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 8.2 Europe Pharmacogenomics Technology (Theranostics & CDx) Market Size by Country (2021-2026)
  3. 8.3 Europe Pharmacogenomics Technology (Theranostics & CDx) Market Size Forecast by Country (2027-2032)
9 Asia-Pacific
  1. 9.1 Asia-Pacific Pharmacogenomics Technology (Theranostics & CDx) Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 9.2 Asia-Pacific Pharmacogenomics Technology (Theranostics & CDx) Market Size by Country (2021-2026)
  3. 9.3 Asia-Pacific Pharmacogenomics Technology (Theranostics & CDx) Market Size Forecast by Country (2027-2032)
10 South America
  1. 10.1 South America Pharmacogenomics Technology (Theranostics & CDx) Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 10.2 South America Pharmacogenomics Technology (Theranostics & CDx) Market Size by Country (2021-2026)
  3. 10.3 South America Pharmacogenomics Technology (Theranostics & CDx) Market Size Forecast by Country (2027-2032)
11 Middle East & Africa
  1. 11.1 Middle East & Africa Pharmacogenomics Technology (Theranostics & CDx) Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 11.2 Middle East & Africa Pharmacogenomics Technology (Theranostics & CDx) Market Size by Country (2021-2026)
  3. 11.3 Middle East & Africa Pharmacogenomics Technology (Theranostics & CDx) Market Size Forecast by Country (2027-2032)
12 Concluding Insights
    13 Appendix
    1. 13.1 Reasons for Doing This Study
    2. 13.2 Research Methodology
    3. 13.3 Research Process
    4. 13.4 Authors List of This Report
    5. 13.5 Data Source
    6. 13.5.1 Secondary Sources
    7. 13.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst